Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291965 · ClinicalTrials.gov registry record
Blood Samples to Identify Biomarkers of Busulfan
A clinical trial, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- 139
- Enrollment target
NCT02291965 is a clinical trial that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 139 participants.
The verdict
NCT02291965 was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- 139 participants
- Enrollment target
Study Summary
Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance. Specific Aim 2: To characterize IV BU metabolism by metabolomics. Specific Aim 3: To identify covariates influencing IV BU pharmacokinetics.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2014-11 |
| Est. Completion | 2024-10-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02291965
The ClinicalTrials.gov registry entry for NCT02291965 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02291965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02291965 about?
NCT02291965 is a clinical study titled "Blood Samples to Identify Biomarkers of Busulfan". Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance. Specific Aim 2: To characterize IV BU metabolism by metabolomics. Specific Aim 3: To identify covariates influencing IV BU pharmacokinetics.
What is the current status of trial NCT02291965?
This trial is currently terminated. The enrollment target is 139 participants. The study started on 2014-11. Estimated completion is 2024-10-07.
Who is sponsoring clinical trial NCT02291965?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.